IMU (ASX) $505m Pfizer deal ... IMU will get there too!

Originally posted by PilbaraBoy: ↑

I know a lot of us long-term IMU shareholders are hurting right now which is why I thought I would post this link to a story that came out yesterday!

https://www.geekwire.com/2018/biotech-startup-kineta-inks-cancer-deal-pfizer-worth-505m/

"Seattle-based biotech startup Kineta today received a leg-up in its efforts to kill cancerous tumors using the immune system. Kineta announced an agreement with drug giant Pfizer that includes $15 million in upfront payments and the possibility of an additional $505 million down the line.
Like other immunotherapies, Kineta’s treatment uses the body’s natural defenses to attack tumors. By convincing tumor cells that they are infected with a virus, the therapy triggers the same virus-fighting RIG-I Pathway that targets the flu."

IMU are undertaking really ground breaking research. There is no doubt that immunotherapy is the next big thing and Imugene is right at the global forefront of it! The financial rewards will no doubt come and all these clowns selling their shares for 2c will kick themselves in 12 months time. We all just need to keep calm, remain patient and have a little faith that our experienced Board and world-renowned clinical researchers know what they are doing.

Expand

Originally posted by PilbaraBoy: ↑

I know a lot of us long-term IMU shareholders are hurting right now which is why I thought I would post this link to a story that came out yesterday!

https://www.geekwire.com/2018/biotech-startup-kineta-inks-cancer-deal-pfizer-worth-505m/

"Seattle-based biotech startup Kineta today received a leg-up in its efforts to kill cancerous tumors using the immune system. Kineta announced an agreement with drug giant Pfizer that includes $15 million in upfront payments and the possibility of an additional $505 million down the line.
Like other immunotherapies, Kineta’s treatment uses the body’s natural defenses to attack tumors. By convincing tumor cells that they are infected with a virus, the therapy triggers the same virus-fighting RIG-I Pathway that targets the flu."

IMU are undertaking really ground breaking research. There is no doubt that immunotherapy is the next big thing and Imugene is right at the global forefront of it! The financial rewards will no doubt come and all these clowns selling their shares for 2c will kick themselves in 12 months time. We all just need to keep calm, remain patient and have a little faith that our experienced Board and world-renowned clinical researchers know what they are doing.

Expand

PilbaraBoy: THANKS for your post!

JIMHO: Hopefully, the deal that IMU will get will be much, much better than the one that Kineta just got. But only time will tell, of course. Meanwhile, it will be very tempting indeed to BUY more IMU stock when the share-price revisits low levels...

All the best to all IMU holders and buyers. Have a relaxing FESTIVE PERIOD time ahead.

wasa

No.	Vol.	Price($)
23	1738258	3.8¢

No.

Vol.

Price($)

1738258

3.8¢

Price($)	Vol.	No.
3.9¢	494405	4

Price($)

Vol.

No.

3.9¢

494405

No.	Vol.	Price($)
18	5665336	0.018
14	3997559	0.017
6	2974375	0.016
10	3219799	0.015
4	497500	0.014

No.

Vol.

Price($)

5665336

0.018

3997559

0.017

2974375

0.016

3219799

0.015

497500

0.014

Price($)	Vol.	No.
0.019	400000	2
0.020	5410946	12
0.021	8494780	17
0.022	8757253	13
0.023	4826614	8

Price($)

Vol.

No.

0.019

400000

0.020

5410946

0.021

8494780

0.022

8757253

0.023

4826614

(20min delay)
Last 3.8¢		Change -0.001(2.56%)		Mkt cap ! $386.7M

Open	High	Low	Value	Volume
3.8¢	3.9¢	3.8¢	$134.8K	3.498M

PilbaraBoy: THANKS for your post! JIMHO: Hopefully, the deal...

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Resolute shares bounce back as second payment made to Mali government to secure workers' release

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

Parkes Au-Cu project to 'transform' Adavale Resources with key targets

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

HotCopper Highlights: Your most watched stocks for Week 48, 2024

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

Buyers (Bids)

Sellers (Offers)

PilbaraBoy: THANKS for your post! JIMHO: Hopefully, the deal...

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Resolute shares bounce back as second payment made to Mali government to secure workers' release

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

Parkes Au-Cu project to 'transform' Adavale Resources with key targets

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

HotCopper Highlights: Your most watched stocks for Week 48, 2024

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

Buyers (Bids)

Sellers (Offers)